Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dnatrix Inc.
Headquarters: Houston, TX, United States of America
Website: http://www.dnatrix.com
Year Founded: 2005
Status: Private
BioCentury | Jan 23, 2023
Management Tracks
Ryali becomes CFO of Codexis
Plus: Levisetti made CMO at Cue, and updates from Qu and Biocrucible
BioCentury | Nov 16, 2021
Data Byte
The oncolytic virus pipeline
At least 49 oncolytic virus therapies now in development behind the sole FDA-approved product
BioCentury | Sep 15, 2021
Management Tracks
Skullerud named CEO at Nordic Nanovector
Plus: Pyxis, ViaCyte, Neogene, AltruBio, Lyra and more
BioCentury | Feb 18, 2021
Management Tracks
Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more
After raising a $130 million series B round last week, pediatric oncology company Day One Biopharmaceuticals LLC hired Charles N. York II as COO and CFO. York was CFO and head of corporate development
BioCentury | Jan 12, 2021
Product Development
OX40L pipeline: Data Byte
Kymab leads the pack among companies targeting OX40L for autoimmune disorders, while Moderna has the most advanced program against the target for cancer. OX40L, the ligand for the OX40 receptor,
BioCentury | Jan 17, 2020
Company News
Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more
BioCentury | Sep 13, 2019
Emerging Company Profile
Valo: adding tumor antigens to oncolytic viruses
Valo’s platforms use physical interactions for viral display of tumor antigens without genetic engineering
Items per page:
1 - 10 of 23